Detail akcie Xencor online

Business Summary: Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Xencor Inc revenues decreased 37% to $110.5M. Net loss increased 75% to $232.6M. Revenues reflect Milestone segment decrease of 61% to $34.5M, Royalties segment decrease of 99% to $600K. Higher net loss reflects Interest Expense increase from $6.2M to $36.6M (expense), Unrealized (loss) gain Investments decrease from $9.3M (income) to $12.4M (expense).